Drug Patents (Class 977/801)
-
Patent number: 11872313Abstract: The present invention encompasses prodrug compositions, nanoparticles comprising one or more prodrugs, and methods of use thereof.Type: GrantFiled: November 5, 2020Date of Patent: January 16, 2024Inventors: Gregory M. Lanza, Dipanjan Pan
-
Patent number: 8715736Abstract: Methods and formulations for treating a condition of the skin by delivering therapeutic formulations to the skin that translocates active substances across the stratum corneum barrier to a targeted skin tissue. The methods and formulations comprise active substances encapsulated within surface modified nanostructured lipid carrier nanoparticles.Type: GrantFiled: April 30, 2009Date of Patent: May 6, 2014Assignee: Florida Agricultural and Mechanical UniversityInventors: Mandip Singh Sachdeva, Ram Patlolla
-
Patent number: 8613929Abstract: The present invention relates to nucleic acids and polypeptides encoded thereby, whose expression is modulated in brain microvascular endothelial cells undergoing early dynamic inflammation-induced changes in blood-brain bather functionality. Such polypeptides are referred to as lipopolysaccharide-sensitive (LPSS) polypeptides. These nucleic acids and polypeptides may be useful in methods for controlling blood-brain bather properties in mammals in need of such biological effects. This includes the diagnosis and treatment of disturbances in the blood-brain/retina barrier, brain (including the eye) disorders, as well as peripheral vascular disorders. Additionally, the invention relates to the use of anti-LPSS polypeptide antibodies or ligands as diagnostic probes, as blood-brain barrier targeting agents or as therapeutic agents as well as the use of ligands or modulators of expression, activation or bioactivity of LPSS polypeptides as diagnostic probes, therapeutic agents or drug delivery enhancers.Type: GrantFiled: July 21, 2011Date of Patent: December 24, 2013Assignee: TO-BBB Holding B.V.Inventors: Pieter J. Gaillard, Albertus G. De Boer, Arjen Brink
-
Patent number: 8431806Abstract: Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in liposomal carriers. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent and cytidine analog encapsulated in said liposomal carriers are useful in achieving a drug retention and a sustained drug release for each therapeutic agent.Type: GrantFiled: September 20, 2011Date of Patent: April 30, 2013Assignee: Celator Pharmaceuticals, Inc.Inventors: Lawrence Mayer, Sharon Johnstone, Troy Harasym
-
Patent number: 8384058Abstract: A battery can be fabricated from a substrate including silicon. This allows the battery to be produced as an integrated unit. The battery includes a anode formed from an array of spaced elongated structures, such as pillars, which include silicon and which can be fabricated on the substrate. The battery also includes a cathode which can include lithium.Type: GrantFiled: August 5, 2011Date of Patent: February 26, 2013Assignee: Nexeon Ltd.Inventor: Mino Green
-
Patent number: 8372427Abstract: A composition that includes nanoparticles with binding affinity for platelets, and methods for using this composition to treat vascular disease are disclosed.Type: GrantFiled: March 5, 2007Date of Patent: February 12, 2013Assignee: Abbott Cardiovascular Systems Inc.Inventors: Florian Niklas Ludwig, Syed Faiyaz Ahmed Hossainy, Stephen Dirk Pacetti
-
Publication number: 20130028962Abstract: Control of the fusion activity of liposomes by adsorbing biocompatible nanoparticles to the outer surface of phospholipid liposomes is disclosed. The biocompatible nanoparticles effectively prevent liposomes from fusing with one another. Release of cargo from the liposome is accomplished via trigger mechanisms that include pH triggers, pore forming toxing triggers and photosensitive triggers. Dermal drug delivery to treat a variety of skin diseases such as acne vulgaris and staph infections is contemplated.Type: ApplicationFiled: September 7, 2012Publication date: January 31, 2013Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Liangfang Zhang, Dissaya Pornpattananangkul, Chun-Ming E. Huang
-
Publication number: 20130028959Abstract: Formulations for preventing the sexual transmission of the HIV virus are provided. In one embodiment, the formulations contain un-conjugated liposomes whose physicochemical properties allow binding to the HIV virus. The liposomes are made up of natural or synthetic lipids, alone or in combination. Preferably, the liposomes are made entirely of cardiolipin. In other embodiments the liposomes are modified to contain Hgands which bind HIV. The method for preventing the sexual transmission of the HIV virus includes self-administration of a formulation containing an effective amount of liposomes which bind to the HIV virus to the surface of a mucosal membrane prior to intercourse.Type: ApplicationFiled: December 16, 2010Publication date: January 31, 2013Applicants: Massachusetts Institute of Technology, Children's Medical Center CorporationInventors: Nikita Kiran Malavia, Daniel S. Kohane
-
Publication number: 20130004561Abstract: The present invention provides an antibody composition comprising ovine antibodies, for use in the prevention or treatment of C. difficile infection wherein the antibodies bind to a C. difficile toxin, and wherein said prevention or treatment is by oral delivery of the antibody composition. Also provided is a pharmaceutical composition of ovine antibodies for oral delivery, which further comprises one or more means for protecting the antibodies from trypsin and/or chymotrypsin and/or stomach acid.Type: ApplicationFiled: December 6, 2010Publication date: January 3, 2013Inventors: Clifford Shone, April Roberts, John Landon
-
Patent number: 8323696Abstract: Nanoparticles that activate complement in the absence of biological molecules are described. The nanoparticles are shown to specifically target antigen presenting cells in specifically in lymph nodes, without the use of a biological molecule for targeting. These particles are useful vehicles for delivering immunotherapeutics. Surface chemistries and chemical formulations for the nanoparticles are described.Type: GrantFiled: August 29, 2008Date of Patent: December 4, 2012Assignee: Ecole Polytechnique Federale de LausanneInventors: Jeffrey A. Hubbell, Conlin P. O'Neil, Sai T. Reddy, Melody A. Swartz, Diana Velluto, André van der Vlies, Eleonora Simeoni
-
Patent number: 8252338Abstract: The present invention provides a synthetic LDL nanoparticle comprising a lipid moiety and a synthetic chimeric peptide so as to be capable of binding the LDL receptor. The synthetic LDL nanoparticle of the present invention is capable of incorporating and targeting therapeutics to cells expressing the LDL receptor for diseases associated with the expression of the LDL receptor such as central nervous system diseases. The invention further provides methods of using such synthetic LDL nanoparticles.Type: GrantFiled: November 13, 2006Date of Patent: August 28, 2012Assignees: The Regents of the University of California, Children's Hospital & Research Center OaklandInventors: Trudy M. Forte, Mina Nikanjam
-
Publication number: 20120195957Abstract: Methods and formulations for treating a condition of the skin by delivering therapeutic formulations to the skin that translocates active substances across the stratum corneum barrier to a targeted skin tissue. The methods and formulations comprise active substances encapsulated within surface modified nanostructured lipid carrier nanoparticles.Type: ApplicationFiled: April 30, 2009Publication date: August 2, 2012Inventors: Mandip Singh Sachdeva, Ram Patlolla
-
Publication number: 20120164065Abstract: A method for treating cancer, preventing cancer or delaying the progression of a cancer in an animal or human comprising the step of: administering to the animal or the human having a cancer a composition in an amount effective to treat cancer, prevent cancer or delay the progression of cancer in the animal or the human. The composition comprises a pharmaceutically acceptable excipient, and ascorbate which is joined to a carrier structure containing an anti-cancer active agent, said carrier structure being capable of releasing the anti-cancer agent in the presence of a reactive oxygen species.Type: ApplicationFiled: January 11, 2012Publication date: June 28, 2012Inventors: Anthony Manganaro, Karen Rockwell
-
Publication number: 20120082616Abstract: The present invention provides targeted delivery compositions and their methods of use in treating and diagnosing a disease state in a subject.Type: ApplicationFiled: September 23, 2011Publication date: April 5, 2012Applicant: Mallinckrodt LLCInventors: Bobby N. Trawick, Todd A. Osiek, James R. Wheatley, JR.
-
Patent number: 8067011Abstract: The present invention provides a targeted multi-layered drug delivery system for the delivery of cytotoxic agents to B-cells.Type: GrantFiled: April 9, 2007Date of Patent: November 29, 2011Assignee: Chimeros, Inc.Inventors: Claude Geoffrey Davis, Miguel A. de los Rios, Kenneth J. Oh, Timothy L. Bullock, Patrick T. Johnson, Jacek Ostrowski
-
Patent number: 8026209Abstract: The present invention relates to nucleic acids and polypeptides encoded thereby, whose expression is modulated in brain microvascular endothelial cells undergoing early dynamic inflammation-induced changes in blood-brain barrier functionality. Such polypeptides are referred to as lipopolysaccharide-sensitive (LPSS) polypeptides herein. These nucleic acids and polypeptides may be useful in methods for controlling blood-brain barrier properties in mammals in need of such biological effects. This includes the diagnosis and treatment of disturbances in the blood-brain/retina barrier, brain (including the eye) disorders, as well as peripheral vascular disorders. Additionally, the invention relates to the use of anti-LPSS polypeptide antibodies or ligands as diagnostic probes, as blood-brain barrier targeting agents or as therapeutic agents as well as the use of ligands or modulators of expression, activation or bioactivity of LPSS polypeptides as diagnostic probes, therapeutic agents or drug delivery enhancers.Type: GrantFiled: February 10, 2004Date of Patent: September 27, 2011Assignee: BBB Holding B.V.Inventors: Pieter Jaap Gaillard, Albertus Gerrit De Boer, Arjen Brink
-
Patent number: 8022279Abstract: Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in liposomal carriers. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent and cytidine analog encapsulated in said liposomal carriers are useful in achieving a drug retention and a sustained drug release for each therapeutic agent.Type: GrantFiled: April 22, 2005Date of Patent: September 20, 2011Assignee: Celator Pharmaceuticals, Inc.Inventors: Lawrence Mayer, Sharon Johnstone, Troy Harasym
-
Patent number: 7964196Abstract: A self-assembling nanoparticle drug delivery system for the delivery of drugs including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the drug, a lipid bi-layer envelope and targeting or facilitating molecules anchored in the lipid bilayer. A method for construction of the self-assembling nanocparticle drug delivery system is also provided.Type: GrantFiled: May 25, 2005Date of Patent: June 21, 2011Assignee: Chimeros, Inc.Inventors: Miguel de los Rios, Kenneth J. Oh
-
Patent number: 7955618Abstract: A pharmaceutical composition for parenteral administration, comprising liposomes composed of non-charged vesicle-forming lipids, including up to 20 mole percent of an amphipathic vesicle-forming lipid derivatized with polyethyleneglycol, and optionally including not more than 10 mole percent of negatively charged vesicle-forming lipids, the liposomes having a selected mean particle diameter in the size range between about 40-200 nm and containing a water soluble corticosteroid for the site-specific treatment of inflammatory disorders, is provided.Type: GrantFiled: June 5, 2003Date of Patent: June 7, 2011Assignee: Enceladus Pharmaceuticals B.V.Inventors: Josbert Maarten Metselaar, Marca Henriette M. Wauben, Gerrit Storm
-
Patent number: 7919113Abstract: A formulation containing one or more lipophilic agents, methods of making and using the formulation are described herein. The formulation is formed by adding a pre-suspension concentrate composition to an aqueous medium. Upon contact with the aqueous medium, a solid nanoparticle suspension spontaneously forms. The resulting formulation is in the form of a microemulsion. The concentrate contains an amphiphilic solvent, a pharmaceutically acceptable solid carrier such as a solid fatty acid or ester, a surfactant, and an agent. Preferably the concentrate contains a combination of a surfactant with a high hydrophilic/lipophilic balance (HLB) of at least about 8 and a surfactant with a low HLB of less than about 5. The agent is preferably a lipophilic drug and other lipophilic ingredient, such as vitamins. The composition is suitable for use in medical and non-medical applications. The microemuslions described herein have increased stability was compared to the prior art.Type: GrantFiled: October 14, 2004Date of Patent: April 5, 2011Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventor: Abraham J. Domb
-
Publication number: 20100310642Abstract: Topical drug delivery systems for ophthalmic use including mixed nanomicellar formulations of water-insoluble drugs and methods of treating diseases affecting the posterior ocular segments are disclosed. In an embodiment, an aqueous ophthalmic solution includes nanomicelles in a physiologically acceptable buffer, having a pH of 5.0 to 8.0, wherein a corticosteroid at a concentration from about 0.01% w/v to about 1.00% w/v is solubilized through entrapment in a mixed micellar hydrophobic core with a corona composed of hydrophilic chains extending from the hydrophobic core, wherein the nanomicelles comprise vitamin E TPGS at a concentration ranging from about 3.0% w/v to about 5.0% w/v stabilized with octoxynol-40 at a concentration ranging from about 1.0% w/v to about 3.0% w/v.Type: ApplicationFiled: May 5, 2010Publication date: December 9, 2010Inventors: Ashim K. Mitra, Poonam R. Velagaleti, Ulrich M. Grau
-
Patent number: 7438903Abstract: Bioavailability of Coenzyme-Q10 (“Co-Q10”), an oil-soluble substance, can be enhanced in a subject by modifying, e.g. nanonizing or charging, the form of Co-Q10. Co-Q10 bioavailability also can be enhanced by administering Co-Q10 to the subject as an oil (lipid)-based and water (hydro)-based mixed composition, along with other optional components, such as oils, resins and other carriers. Accordingly, the invention provides various Co-Q10 compositions, e.g. compositions comprised of (i) Co-Q10 dissolved in one or more Co-Q10-soluble oils and (ii) Co-Q10 in admixture with at least one water-dispersible agent. A Co-Q10 complex of the invention, therefore, yields an increased cell absorption rate, as well as an enhanced percentage of Co-Q10 peak absorption, compared to previously known compounds. Methods for making and using the aforementioned compositions also are provided.Type: GrantFiled: May 7, 2004Date of Patent: October 21, 2008Assignee: NBTY, Inc.Inventor: Daryoush Parkhideh
-
Publication number: 20080220055Abstract: A composition that includes nanoparticles with binding affinity for platelets, and methods for using this composition to treat vascular disease are disclosed.Type: ApplicationFiled: March 5, 2007Publication date: September 11, 2008Inventors: Florian Niklas Ludwig, Syed Faiyaz Ahmed Hossainy, Stephen Dirk Pacetti
-
Patent number: 7371738Abstract: The present invention relates to the development of a hyaluronic acid and hyaluronic acid hybrid nanoparticle systems for the administration of active molecules, peptides, DNA and/or other hydrophilic or hydrophobic molecules, the composition of hyaluronic acid and hyaluronic acid hybrid nanoparticle systems, and the procedure for their development and use. These nanoparticles are made up of hyaluronic acid in salt form, preferentially the sodium salt of the polymers or hybridized with magnetic Fe particles. The nanoparticles are basically from natural polymers, biocompatibles and biodegradables. The nanoparticles allow the controlled release of the active molecules they transport and their orientation towards the target tissues. The present invention teaches a procedure to elaborate particles of hyaluronic acid with a diameter less than 180 nm., that incorporate an active ingredient, independent of its hydrophilic or hydrophobic nature. Procedures to produce the particles are described.Type: GrantFiled: April 17, 2006Date of Patent: May 13, 2008Assignee: University of South FloridaInventors: Shyam S. Mohapatra, Bishwabhusan Sahoo, Arun Kumar, Sumita Behera
-
Patent number: 7329807Abstract: The present invention relates to novel fusogenic vesicles as highly efficient and versatile encapsulation systems for delivering a substance of choice, such as nucleic acids, proteins, peptides, antigens, pharmaceutical drugs and cosmetic agents to cells and tissues.Type: GrantFiled: November 21, 2003Date of Patent: February 12, 2008Assignee: Pevion Biotech Ltd.Inventors: Sonia Vadrucci, Joseph Brunner, Rinaldo Zurbriggen